Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215891 | 1.00 | MAPT (0.62) | MAPTHPGDALDH1A1LMNAPOLB | |
| SCHEMBL7965807 | 0.88 | GAA (0.64) | MAPTHPGDALDH1A1LMNAPOLB | |
| SCHEMBL7965720 | 0.85 | HPGD (0.56) | MAPTHPGDALDH1A1LMNAPOLB | |
| SCHEMBL3213207 | 0.78 | MEN1 (0.55) | MEN1KMT2A | |
| SCHEMBL3213179 | 0.78 | MEN1 (0.55) | MEN1KMT2A | |
| SCHEMBL13491783 | 0.78 | GAA (0.67) | POLBGAAMEN1KMT2A | |
| SCHEMBL13491926 | 0.78 | LMNA (0.75) | MAPTHPGDALDH1A1LMNAPOLB | |
| SCHEMBL13491885 | 0.77 | POLB (0.61) | MAPTHPGDALDH1A1POLBGAA | |
| SCHEMBL13491767 | 0.76 | — | — | |
| SCHEMBL3211952 | 0.76 | GAA (0.70) | ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783521-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20140038951-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2014-02-06 | — | — | US | disclosed |
| US-8377930-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100035872-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038951-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | MAPT 229/4885HPGD 785/4885ALDH1A1 2053/4885 |
| US-20100035872-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | MAPT 229/4885HPGD 785/4885ALDH1A1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.